{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-013888","form_type":"8-K","ticker":"OGN","cik":"0001821825","company_name":"Organon & Co.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.350589+00:00","generated_at":"2026-05-16T03:05:56.275891+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Organon reports FY2025 rev $6.2B (-3%), GAAP EPS $0.72; guides FY2026 rev ~$6.2B, Adj EBITDA ~$1.9B","bullets":["Full year 2025 revenue $6.2B, down 3% YoY; GAAP diluted EPS $0.72, adjusted diluted EPS $3.66.","Q4 2025 revenue $1.507B (-5% as-reported, -8% ex-FX); Q4 GAAP net loss $205M vs income $109M prior year; adjusted diluted EPS $0.63 vs $0.90.","Women's Health Q4 revenue down 15%, Nexplanon down 20% ex-FX due to ceased U.S. wholesaler practices and policy access restrictions.","Biosimilars Q4 revenue up 11%, led by Hadlima and new assets (Bildyos, Bilprevda, Tofidence).","FY2026 guidance: revenue ~$6.2B, Adjusted EBITDA ~$1.9B, both in line with FY2025 performance."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-013888","json":"https://secwatch.observer/filing/0001104659-26-013888.json","markdown":"https://secwatch.observer/filing/0001104659-26-013888.md","text":"https://secwatch.observer/filing/0001104659-26-013888.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821825/000110465926013888/0001104659-26-013888-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821825/000110465926013888/tm266144d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:05:56.275891+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}